drugset / Trial / NCT01249404

Dysport® Adult Lower Limb Spasticity Study

NCT01249404 ↗

Phase 3 Completed 388 enrolled Ipsen
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this research study is to assess the efficacy of Dysport® compared to placebo in improving muscle tone in hemiparetic subjects with lower limb spasticity due to stroke or traumatic brain injury.

Timeline

Start
2011-03
Primary completion
2013-12
Completion
2014-05

Outcome

Met primary endpoint

registry analysis (unspecified test); Dysport® 1500 U vs Placebo; p =0.0091; LS mean difference -0.3 (95% CI -0.5 to -0.1); ANCOVA NCT01249404 ↗

paper single abobotulinumtoxinA (Dysport Ipsen) administration reduced muscle tone. PMID 29093068 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 1000 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 1500 iu Intramuscular

Indications

No indication recorded.